Formestane, a steroidal aromatase inhibitor after failure of non-steroidal aromatase inhibitors (anastrozole and letrozole): Is a clinical benefit still achievable?

Annals of Oncology

Volumn 12, Issue 11, 2001, Pages 1539-1543

  Carlini, P ^a   Frassoldati, A ^b   Marco, S De ^a   Casali, A ^a   Ruggeri, E M ^a   Nardi, M ^a   Papaldo, P ^a   Fabi, A ^a   Paoloni, F ^a   Cognetti, F ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Advanced metastatic; Anastrozole; Aromatase inhibitors; Breast cancer; Formestane; Hormone therapy; Letrozole

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; AROMATASE INHIBITOR; EXEMESTANE; FORMESTANE; LETROZOLE; MEDROXYPROGESTERONE; STEROID; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; HORMONAL THERAPY; HUMAN; METASTASIS; MULTICENTER STUDY; POPULATION RESEARCH; POSTMENOPAUSE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT FAILURE;

ADULT; AGED; ANDROSTENEDIONE; ANTINEOPLASTIC AGENTS; AROMATASE INHIBITORS; BREAST NEOPLASMS; CLINICAL TRIALS; DISEASE PROGRESSION; ENZYME INHIBITORS; FEMALE; HUMANS; MIDDLE AGED; NITRILES; POSTMENOPAUSE; RECEPTORS, ESTROGEN; RETROSPECTIVE STUDIES; TREATMENT FAILURE; TRIAZOLES;

EID: 0035690056     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1013180214359     Document Type: Article

References (31)

1. Recent advances in endocrine therapy of breast cancer
2. Aromatase inhibitors in advanced breast cancer: Mechanism of action and clinical implications
3. Use of aromatase inhibitors in postmenopausal women with advanced breast cancer
4. Aromatisation of androgens by human breast cancer
5. Oestrogen formation in breast: Clinical and biological importance
6. Letrozole, a new oral aromatase inhibitor: Randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer
7. Low-dose amino-glutethimide in treatment of advanced breast cancer
8. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: Double-blind, random trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate
9. Anastrozole vs. megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma
10. The third-generation non-steroidal aromatase inhibitors: A review of their clinical benefits in the second-line hormonal treatment of advanced breast cancer
11. Tumour response and oestrogen suppression in breast cancer patients treated with aromatase inhibitors
12. Aromatase inhibition with 4-OHAndrostenedione after prior aromatase inhibition with aminoglutethimide in women with advanced breast cancer
13. Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: A phase II, multicentre multinational study
14. The influence of aminoglutethimide on plasma oestrogen levels in breast cancer patients on 4-hydroxyandroste-nedione treatment
15. Treatment with formestane alone and in combination with aminoglutethimide in heavily pretreated cancer patients
16. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: A phase II trial
17. Anastrozole shows evidence of activity in postmenopausal patients who have responded or stabilised on formestane therapy
18. A clinical trial of amino-glutethimide in advanced postmenopausal breast carcinoma: Low response in patients previously treated with medroxyprogesterone
19. Second and third line hormonotherapy in advanced post-menopausal breast cancer: A multicenter random trial comparing medroxyprogesterone acetate with aminoglutethimide in patients who have become resistant to tamoxifen
20. Response to third-line endocrine treatment for advanced breast cancer
21. Multicenter phase II trial of exemestane as third-line hormonal therapy of postmenopausal women with metastatic breast cancer
22. A random phase II trial of two dosage levels of letrozole as third-line hormonal therapy for women with metastatic breast carcinoma
23. Efficacy of anastrozole in a consecutive series of advanced breast cancer patients treated with multiple, prior chemotherapies and endocrine agents: M.D. Anderson Cancer Center Experience
24. Evaluation of the cancer patient and the response to treatment
25. Assessment of response to treatment in advanced breast cancer
26. The clinical relevance of static disease (no change) category for six months on endocrine therapy in patients with breast cancer
27. Anastrozole vs. tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: Results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability Study
28. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: Results of a North American multi-center random trial
29. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: Results of a phase III random double-blind trial
30. High activity and tolerability demonstrated for exemestane in postmenopausal women with metastatic breast cancer who had previously failed on tamoxifen treatment
31. Paradoxical effects of aromatase inhibitors: Increased activity of target enzyme following prior exposure to some but not all aromatase inhibitors